Efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients.

CONCLUSION: Bevacizumab combined with nedaplatin has good efficacy in the treatment of ovarian cancer, which can significantly improve the tumor markers, enhance the immunity and ameliorate the QoL of patients, with fewer adverse reactions, so it is worthy of popularization and application. PMID: 32277617 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32277617?dopt=Abstract

Source: Journal of B.U.ON. - April 13, 2020 Category: Cancer & Oncology Tags: J BUON Source Type: research